Araceli Biosciences Welcomes New CEO Matt Beaudet

Araceli Biosciences, a leader in cell-based screening and analysis technologies, is excited to announce the appointment of Matthew (Matt) Beaudet as the new President and Chief Executive Officer. Officially taking the helm at Araceli, Matt brings with him extensive experience and a proven track record in the biotech sector, developed over more than twenty years of industry leadership at companies including Molecular Probes, Invitrogen, and Life Technologies. Notably, he has previously excelled as the CEO of InVivo Biosystems, where he was instrumental in raising significant capital for growth, guiding the company to successfully commercialize innovative fluorescence-based assays and instrument platforms.

Bill Cortelyou, Chairman of the Board, expressed the board's confidence in Matt's capabilities, highlighting his commitment to innovation in the Oregon biotechnology community and his history of developing transformative technologies. Matt's appointment is expected to initiate a new phase of growth and advancements for Araceli Biosciences, focusing on the acceleration of therapeutic discoveries. Reflecting on his new role, Beaudet expressed gratitude for the trust placed in him and enthusiasm for the future, aiming to elevate the pace of drug development and redefine potential achievements within the biotech sector.